# US Neurodegenerative Disease Market

> US Neurodegenerative Disease Market Research Report By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions) and By Route of Administration (Oral, Injectable, Intravenous, Transdermal) -Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.05%
- **2024:** $ 14.5 Billion
- **2025:** $ 15.67 Billion
- **2035:** $ 34 Billion
- **Key Players:** Biogen (US), Eli Lilly (US), Roche (CH), Novartis (CH), AstraZeneca (GB), Merck & Co. (US), Amgen (US), Sanofi (FR), AbbVie (US)

**Report ID:** MRFR/LS/51020-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-neurodegenerative-disease-market-52780

---

## Market Summary

## **US Neurodegenerative Disease Market Overview**

As per MRFR analysis, the US Neurodegenerative Disease Market Size was estimated at 4.25 (USD Billion) in 2023.The US Neurodegenerative Disease Market Industry is expected to grow from 4.8(USD Billion) in 2024 to 9 (USD Billion) by 2035. The US Neurodegenerative Disease Market CAGR (growth rate) is expected to be around 5.881% during the forecast period (2025 - 2035).

**Key US Neurodegenerative Disease Market Trends Highlighted**

The US Neurodegenerative Disease Market is currently influenced by several vital trends. One prominent trend is the increasing investment in research and development of novel therapies, particularly for conditions such as Alzheimer's and Parkinson's diseases. This investment is largely driven by the aging population in the US, as the prevalence of neurodegenerative diseases rises with age. In addition, advancements in biotechnology are propelling the discovery of new drugs and treatment modalities, further shaping the market landscape. Key market drivers include heightened awareness and education regarding neurodegenerative diseases among healthcare providers and the general public.

This increased understanding is leading to earlier diagnosis and intervention, which is essential for improving patient outcomes. Additionally, government initiatives supporting research funding and partnerships between public institutions and private companies facilitate progress in treatment options. The establishment of special task forces and funding programs by the National Institutes of Health (NIH) also plays a crucial role in advancing research efforts. Moreover, opportunities exist for the development of personalized medicine approaches in the US. Tailoring treatments to individual genetic profiles may vastly improve efficacy and patient satisfaction.

The surge of digital health technologies, such as telemedicine and mobile health applications, is also paving the way for better disease management strategies, allowing patients to monitor their symptoms and treatment adherence more conveniently.  
Recent trends show a shift toward collaboration between various stakeholders, including academia, pharmaceutical companies, and patient advocacy groups. This cooperative approach not only enhances research efforts but also ensures that the voices of patients are considered in the development of new therapies. Overall, the US Neurodegenerative Disease Market is evolving, with an emphasis on innovation and improved patient care.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

**US Neurodegenerative Disease Market Drivers**

**Increasing Prevalence of Neurodegenerative Diseases**

The US Neurodegenerative Disease Market Industry is expanding rapidly due to the rising frequency of neurodegenerative disorders such as Alzheimer's Disease and Parkinson's Disease. According to the Centers for Disease Control and Prevention (CDC), around 5.8 million Americans aged 65 and older have Alzheimer's disease, which is anticipated to increase to over 14 million by 2060. The expanding aging population, along with enhanced diagnostic skills, is predicted to further increase this number. Organizations such as the Alzheimer's Association are spending extensively on R&D activities to discover improved treatments and prevention measures, highlighting the need for breakthrough cures.

Furthermore, it is anticipated that the economic impact of Alzheimer's disease alone will be $1.1 trillion by 2050, emphasizing the critical need for effective solutions in the US neurodegenerative disease market.

**theAdvancements in Research and Development**

The US Neurodegenerative Disease Market Industry is significantly driven by advancements in Research and Development, particularly in therapeutic interventions. Major pharmaceutical companies such as Biogen and Eli Lilly are investing in cutting-edge technologies and novel drug discovery to combat neurodegenerative diseases. As of recent years, funding for dementia-related Research and Development has increased considerably, with the National Institute on Aging (NIA) supporting over $2.8 billion in Alzheimer’s research alone for fiscal year 2022. This surge in funding is designed to expedite the development of innovative treatment options, providing hope for patients and families affected by these diseases.

This ongoing commitment to enhancing therapeutic strategies highlights the increasing potential for market growth.

**Growing Healthcare Awareness**

The rising awareness of neurodegenerative diseases in the US is positively impacting the US Neurodegenerative Disease Market Industry. Public health campaigns and initiatives led by organizations like the Mayo Clinic and the National Institute of Health (NIH) aim to educate people about the symptoms, risks, and importance of early diagnosis and treatment. A reported increase of nearly 20% in annual health screenings for cognitive disorders reflects this growing awareness, with more individuals seeking medical advice sooner.

As more people become informed about these debilitating conditions, demand for diagnostic services and therapeutic options is expected to surge, driving growth within the market.

**Emerging Technologies in Diagnostics**

The incorporation of emerging technologies in diagnostics is set to propel the US Neurodegenerative Disease Market Industry forward. The introduction of biomarker testing, advanced imaging techniques, and artificial intelligence applications in diagnostic processes is revolutionizing how neurodegenerative diseases are diagnosed. For instance, the FDA recently approved a pioneering blood test for the early detection of Alzheimer's Disease, which demonstrates the ongoing innovations in this sector. The medical community anticipates that the use of such advanced diagnostic tools will lead to earlier detection rates upwards of 70%, allowing for timely interventions.

This shift toward precision medicine and improved diagnostic methodologies not only benefits patients but also enhances the market landscape as companies focus on developing these technologies.

**US Neurodegenerative Disease Market Segment Insights**

**Neurodegenerative Disease Market Disease Type Insights**  

The US Neurodegenerative Disease Market, specifically focusing on the Disease Type segment, encompasses a range of complex and debilitating conditions that are primarily characterized by progressive degeneration of the nervous system. Among these, Alzheimer's Disease is particularly significant, being the most common form of dementia, impacting millions of individuals and demanding extensive healthcare resources for both treatment and caregiving. Following closely is Parkinson's Disease, which affects movement and motor skills, and poses unique challenges both for patients and caregivers, often leading to a need for long-term therapy and advanced care strategies.

Additionally, Multiple Sclerosis represents a category that primarily affects young adults, often leading to a significant impact on the workforce and general quality of life, necessitating peer support and rehabilitation services. Amyotrophic Lateral Sclerosis, known for its aggressive progression, has drawn attention due to its severe loss of motor function, which not only affects patients but also strains the families and communities involved in their care. Huntington's Disease, which has genetic origins, creates a critical dialogue regarding genetic counseling and the future outlook for families at risk, emphasizing the importance of ongoing research and clinical studies.

The US Neurodegenerative Disease Market segmentation reflects a growing acknowledgment of not just the medical needs but also the socio-economic implications of these diseases. With an increasing elderly population in the US, the burden of these neurodegenerative diseases is expected to rise, driving innovation, therapeutic advancements, and comprehensive care strategies tailored to each condition. Moreover, each disease type comes with its own set of healthcare challenges and treatment landscapes, which could be influenced by factors such as trends in home healthcare, advanced diagnostics, and lifestyle modifications that aim to mitigate risk factors.

As public awareness increases and advocacy groups push for more research funding, the landscape for these diseases is evolving, presenting both significant opportunities for industry growth and challenges in meeting diverse patient needs. The US Neurodegenerative Disease Market continues to adapt to these shifts, highlighting the critical role of early diagnosis, personalized medicine, and holistic support systems that encompass not only physical health but also mental and emotional well-being for patients and their families.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

**Neurodegenerative Disease Market Diagnosis Method Insights  **

The Diagnosis Method segment of the US Neurodegenerative Disease Market plays a crucial role in identifying and differentiating various neurodegenerative disorders. This segment encompasses several techniques, including Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, and Electrophysiological Tests. Neurological Examinations are fundamental, enabling clinicians to assess patients through cognitive and physical tests, which aid in early detection and management. Imaging Techniques, such as MRI and PET scans, are vital for visualizing brain structure and function, facilitating accurate diagnosis by revealing abnormalities typical of conditions like Alzheimer's and Parkinson's diseases.

Cerebrospinal Fluid Analysis provides critical information from the fluid surrounding the brain and spinal cord, highlighting biomarkers associated with neurodegeneration. Electrophysiological Tests assess the electrical activity of the brain and nerves, offering insights into functional impairments. Together, these diagnostic methods enhance our understanding, offering healthcare professionals the tools necessary for a precise diagnosis, which is essential for developing effective treatment plans in the growing field of neurodegenerative disease management. As the demand for effective diagnostics rises, these methodologies are becoming increasingly significant within the US Neurodegenerative Disease Market.

Neurodegenerative Disease Market Treatment Type Insights  

The Treatment Type segment of the US Neurodegenerative Disease Market encompasses various approaches to managing neurodegenerative conditions, including Medication, Therapy, Rehabilitation, and Surgical Interventions. Medication plays a critical role, focusing on the use of pharmacological therapies to slow disease progression and alleviate symptoms, thereby offering significant benefits to patients. Therapy, which includes cognitive and physical therapies, is vital for enhancing the quality of life and helping patients retain functional abilities. Rehabilitation is also a key component, aimed at restoring independence and functionality to individuals experiencing motor and cognitive impairments resulting from neurodegenerative diseases.

Surgical Interventions, though less common, can be pivotal in specific cases, offering potential solutions for patients with advanced stages of disease. This segment is influenced by the increasing prevalence of neurodegenerative diseases in the US, driven by an aging population and changes in lifestyle. The ongoing Research and Development efforts are poised to introduce innovative treatment modalities, creating new opportunities for improved patient outcomes and market evolution. As this segment progresses, it will be essential to address challenges such as treatment accessibility, affordability, and the need for personalized approaches tailored to individual patient needs.

**Neurodegenerative Disease Market Route of Administration Insights  **

The Route of Administration segment is a crucial aspect of the US Neurodegenerative Disease Market, encompassing various methods such as Oral, Injectable, Intravenous, and Transdermal. Each of these methods showcases unique advantages that facilitate patient compliance and treatment efficacy. Oral administration remains a popular choice due to its ease of use and convenience for patients, significantly impacting medication adherence rates. Injectable methods provide rapid therapeutic action, essential for conditions requiring immediate relief, while Intravenous administration is particularly beneficial in clinical settings, allowing for direct and swift delivery of medication.

Transdermal delivery systems offer the advantage of prolonged release and steady drug levels, contributing to improved convenience for chronic patients. The growing prevalence of neurodegenerative diseases, along with advancements in pharmaceutical formulations, is further driving the development and adoption of diverse routes of administration in the US market. This segment is vital for overall treatment strategies, enhancing patient experience and outcomes in managing these complex conditions. With continuous research and development, the evolution of administration methods is expected to provide innovative solutions that align with the rising patient population and their unique needs.

**US Neurodegenerative Disease Market Key Players and Competitive Insights**

The US Neurodegenerative Disease Market is characterized by a diverse landscape of innovative companies working to address various conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis. With an increasing prevalence of these disorders and a growing elderly population, the market is witnessing significant investment in research and development aimed at discovering novel therapeutic solutions. The competitive dynamics are shaped by a mix of established pharmaceutical companies and emerging biotech firms, all vying for market share and striving to bring groundbreaking treatments to patients.

Evolving technologies, regulatory changes, and shifting patient needs continue to influence the direction of the industry, making it imperative for companies to adapt and innovate. Vertex Pharmaceuticals holds a notable position within the US Neurodegenerative Disease Market, leveraging its research expertise and strong clinical development capabilities to create impactful therapies. The company is recognized for its focus on developing treatments tailored to specific patient populations, which enhances its appeal among healthcare providers and patients alike. Vertex's commitment to addressing unmet needs in neurodegenerative disorders is reflected in its robust pipeline and strategic collaborations aimed at accelerating drug development.

The company benefits from a solid financial foundation and a reputation for scientific excellence that enhances its competitive edge, enabling it to efficiently navigate the complexities of the neurodegenerative disease landscape. Acadia Pharmaceuticals is also a key player in the US Neurodegenerative Disease Market, with a clear focus on central nervous system disorders. Known for its flagship product targeting Parkinson's disease, Acadia has built a strong presence within the market by offering innovative therapies that improve treatment outcomes for patients.

The company's dedication to advancing the care for neurodegenerative diseases is underscored by its commitment to research and development, reflecting the strengths of a dedicated clinical team. Strategic partnerships and acquisitions have played a crucial role in expanding Acadia's product offerings and enhancing its research capabilities. This proactive approach not only strengthens Acadia's market presence but also positions the company as a formidable competitor in the evolving landscape of neurodegenerative disease treatment in the US.

**Key Companies in the US Neurodegenerative Disease Market Include**

**US Neurodegenerative Disease Market Industry Developments**

In recent developments within the US Neurodegenerative Disease Market, a notable focus has been on Vertex Pharmaceuticals and Acadia Pharmaceuticals, which are advancing their pipelines for treatments related to various neurodegenerative conditions. In October 2023, AbbVie announced positive results from a phase 3 study for its Alzheimer’s drug, indicating progress in addressing cognitive decline. Furthermore, Biogen and Eli Lilly are engaged in collaborative Research and Development efforts aimed at innovative therapies for Alzheimer’s and related disorders, showcasing the trend of strategic partnerships in the industry.

Recent acquisitions include Amgen's strategic purchase of a biotech firm in August 2023, aiming to enhance its capabilities in neurodegenerative disease therapies. Acorda Therapeutics continues to experience growth attributed to its market strategies and product offerings, reflecting a broader trend of increasing market valuation across the sector, which is projected to expand significantly in the coming years. The ongoing investments and mergers signal a robust activity in tackling neurodegenerative diseases, with significant implications for patients and healthcare providers in the US. Major market players such as Roche and Novartis maintain competitive momentum through innovative clinical trials and product launches.

**Neurodegenerative Disease Market Segmentation Insights**

## Market Drivers

### Regulatory Support and Incentives

Regulatory support and incentives play a pivotal role in shaping the neurodegenerative disease market. The U.S. Food and Drug Administration (FDA) has implemented various programs aimed at expediting the approval process for therapies targeting neurodegenerative conditions. Initiatives such as the Breakthrough Therapy Designation and Fast Track designation are designed to facilitate the development of promising treatments. This regulatory environment encourages pharmaceutical companies to invest in research and development, potentially leading to a more robust pipeline of therapies. As a result, the neurodegenerative disease market is likely to benefit from an influx of innovative treatment options in the coming years.

### Increased Focus on Drug Development

The neurodegenerative disease market is witnessing a surge in drug development efforts, driven by the urgent need for effective treatments. Pharmaceutical companies are increasingly investing in research to develop novel therapies targeting the underlying mechanisms of diseases such as Alzheimer's and Huntington's. The market for neurodegenerative drugs is projected to reach $50 billion by 2027, reflecting a robust pipeline of investigational drugs. This focus on drug development is not only fostering innovation but also attracting significant venture capital investment, which may further accelerate advancements in the neurodegenerative disease market.

### Advancements in Diagnostic Technologies

Technological advancements in diagnostic tools are transforming the neurodegenerative disease market. Innovations such as advanced imaging techniques and biomarker identification are enabling earlier and more accurate diagnoses. For instance, the use of PET scans and MRI has improved the detection of neurodegenerative diseases, allowing for timely intervention. The market for diagnostic tools is expected to grow at a CAGR of around 8% through the next decade, reflecting the increasing emphasis on precision medicine. Enhanced diagnostic capabilities not only facilitate better patient outcomes but also drive demand for subsequent therapeutic options, thereby expanding the overall neurodegenerative disease market.

### Aging Population and Increased Incidence

The aging population in the United States is a critical driver of the neurodegenerative disease market. As individuals age, the risk of developing neurodegenerative conditions such as Alzheimer's and Parkinson's disease escalates. Current estimates suggest that by 2030, approximately 20% of the U.S. population will be over 65 years old, leading to a projected increase in the prevalence of these diseases. This demographic shift is likely to create a substantial demand for innovative therapies and care solutions within the neurodegenerative disease market. Furthermore, the economic burden associated with these diseases is significant, with costs projected to exceed $1 trillion annually by 2050, emphasizing the urgent need for effective interventions.

### Growing Awareness and Education Initiatives

There is a notable increase in awareness and education initiatives surrounding neurodegenerative diseases, which is positively impacting the market. Campaigns aimed at educating the public about the symptoms and early signs of these conditions are crucial for early diagnosis and treatment. Organizations and healthcare providers are increasingly investing in outreach programs, which may lead to a higher rate of diagnosis and treatment initiation. This heightened awareness is likely to contribute to a growing patient population seeking care, thereby driving the neurodegenerative disease market. As more individuals become informed, the demand for both therapeutic and supportive services is expected to rise.

## Future Outlook

The [Neurodegenerative Disease Market](https://www.marketresearchfuture.com/reports/neurodegenerative-disease-market-19218) is projected to grow at 8.05% CAGR from 2025 to 2035, driven by advancements in therapeutics, increasing prevalence, and enhanced diagnostic technologies.

**New opportunities:**

- Development of personalized medicine solutions for neurodegenerative disorders. Expansion of telehealth services for remote patient monitoring and consultations. Investment in AI-driven drug discovery platforms targeting neurodegenerative diseases.

By 2035, the neurodegenerative disease market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Disease Type: Alzheimer's Disease (Largest) vs. Parkinson's Disease (Fastest-Growing)

In the US neurodegenerative disease market, Alzheimer's Disease holds a significant share, being recognized as the largest segment. This market share reflects the substantial impact and prevalence of Alzheimer's on the population, driving extensive research & development efforts. Parkinson's Disease, on the other hand, has been gaining traction and is identified as the fastest-growing segment, showcasing a rising interest in its treatment options and the increasing number of diagnosed cases.

The growth trends in this segment are influenced by various factors, including aging populations and advancements in technology leading to improved diagnostic methods. Increased awareness about neurodegenerative diseases is also a critical driver, prompting earlier diagnoses and treatment interventions. Furthermore, pharmaceutical companies are investing more in innovative therapies for both Alzheimer's and Parkinson's, pushing these segments further into the spotlight of the US neurodegenerative disease market.

Alzheimer's Disease (Dominant) vs. Parkinson's Disease (Emerging)

Alzheimer's Disease remains the dominant force in the US neurodegenerative disease market, characterized by a high prevalence and significant societal impact. Its long-standing recognition has led to a steady pipeline of therapies aimed at managing symptoms and slowing disease progression. This segment is characterized by a broad range of treatment options, including traditional medications and emerging therapies that target underlying disease mechanisms. On the other hand, Parkinson's Disease is rapidly emerging, driven by increasing diagnosis rates and a growing awareness of the disease's complexities. The focus on innovative treatment approaches is solidifying its position within the market. Enhanced funding for research and the development of personalized medicine strategies are key components shaping both segments' futures.

### By Diagnosis Method: Neurological Examination (Largest) vs. Imaging Techniques (Fastest-Growing)

The US neurodegenerative disease market segment for diagnosis methods showcases a diverse landscape. Neurological examinations maintain the largest market share, attributed to their long-standing role in diagnosing conditions like Alzheimer's and Parkinson's. Imaging techniques, while currently smaller in share, are rapidly gaining traction due to advancements in technology and the increasing need for accurate and early diagnosis.

In recent years, there has been a significant increase in the adoption of imaging techniques, driven by technological advancements such as MRI and PET scans that provide detailed insights into neurodegenerative conditions. Moreover, the growing prevalence of neurodegenerative diseases has led to greater emphasis on timely and reliable diagnosis, further fueling the growth of segments like cerebrospinal fluid analysis and electrophysiological tests, which are also vital in this market.

Neurological Examination (Dominant) vs. Imaging Techniques (Emerging)

Neurological examinations are the dominant method for diagnosing neurodegenerative diseases, relying primarily on patient history and clinical assessments to identify symptoms and impairments. This method remains widely trusted due to its direct engagement with patients and the ability to observe symptoms in real-time. Conversely, imaging techniques represent an emerging trend within the market; they leverage advanced technologies to visualize brain structures and functions. Techniques like MRI and CT scans are becoming essential for accurate diagnosis, supporting neurological examinations by providing critical visual data that enhances understanding of disease progression. As these technologies advance, they are expected to grow significantly in market share, reflecting the shift towards more comprehensive diagnostic approaches.

### By Treatment Type: Medication (Largest) vs. Therapy (Fastest-Growing)

The Treatment Type segment in the US neurodegenerative disease market is characterized by a diverse array of approaches including Medication, Therapy, Rehabilitation, and Surgical Interventions. Among these, Medication holds the largest share, making it the primary treatment option for many patients. Therapy, while smaller in current market share, has emerged rapidly due to increasing awareness and validation of non-pharmacological approaches in neurodegeneration treatment, indicating a dynamic shift in the treatment paradigms.

Recent trends indicate a significant growth trajectory for Therapy, driven by innovations in personalized treatment plans and a greater focus on improving quality of life for patients. Additionally, a growing emphasis on holistic approaches to neurodegenerative conditions has fueled interest and investment in Therapy. As the landscape evolves, Rehabilitation and Surgical Interventions are also gaining traction, albeit at a slower pace, as they complement the primary treatment modalities.

Medication (Dominant) vs. Therapy (Emerging)

Medication as the dominant segment leverages established pharmacological advances to treat conditions such as Alzheimer's and Parkinson's effectively, ensuring a high level of reliance from healthcare providers. Its comprehensive nature addresses various symptoms and stages of neurodegeneration, giving it an edge in clinical settings. Meanwhile, Therapy is positioned as an emerging force, increasingly recognized for its efficacy in enhancing cognitive function and emotional well-being. As non-invasive techniques become more sophisticated, Therapy is receiving more attention and investment, particularly in conjunction with Medication. This synergy enhances patient outcomes and underpins the ongoing evolution of treatment strategies within the US neurodegenerative disease market.

### By Route of Administration: Oral (Largest) vs. Injectable (Fastest-Growing)

The US neurodegenerative disease market demonstrates diverse preferences in routes of administration, with oral administration being the largest segment. This preference is attributed to patient convenience and ease of use, allowing for wider compliance. Injectable routes follow, primarily influenced by specific therapeutic needs and the effectiveness of delivery systems that target complex conditions.

Growth trends indicate a substantial rise in the injectable segment, driven by advances in formulation technologies and an increasing focus on biologics. Patients may also prefer transdermal options for chronic conditions, enhancing their treatment experience. As healthcare systems evolve, the demand for formulations that offer rapid onset and sustained therapeutic outcomes contributes to the growth of these segments.

Oral (Dominant) vs. Injectable (Emerging)

Oral administration has established itself as the dominant route in the US neurodegenerative disease market, favored by patients for its simplicity and non-invasive nature. This segment includes various formulations such as tablets and capsules, providing flexibility and comfort for long-term treatment. On the other hand, the injectable segment is emerging rapidly, driven by the need for more effective delivery of therapeutics that may otherwise be ineffective through oral routes. Innovations in delivery systems, along with an increasing volume of biologics entering the market, are enhancing the appeal of injectables. As these segments evolve, they reflect the changing dynamics of patient preferences and treatment needs.

## Competitive Benchmarking

The neurodegenerative disease market is characterized by intense competition and rapid innovation, driven by an increasing prevalence of conditions such as Alzheimer's and Parkinson's disease. Key players are focusing on advanced therapeutic solutions, with a notable emphasis on biologics and personalized medicine. Companies like Biogen (US) and Eli Lilly (US) are at the forefront, leveraging their robust R&D capabilities to develop novel treatments. Biogen, for instance, has been concentrating on enhancing its pipeline of disease-modifying therapies, while Eli Lilly is investing heavily in partnerships to accelerate drug development. This strategic positioning fosters a competitive environment where innovation is paramount, and companies are compelled to differentiate themselves through unique offerings and advanced technologies.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several players vying for market share. However, the influence of major companies like Roche (CH) and Novartis (CH) remains substantial, as they continue to expand their portfolios through strategic acquisitions and collaborations, thereby shaping the overall market dynamics.
In October Roche (CH) announced a collaboration with a leading biotech firm to develop a novel gene therapy aimed at treating rare neurodegenerative disorders. This strategic move is significant as it not only diversifies Roche's product offerings but also positions the company as a pioneer in gene therapy, potentially leading to breakthroughs in treatment options that could redefine patient care in this space. The collaboration underscores Roche's commitment to innovation and its proactive approach to addressing unmet medical needs.
In September Eli Lilly (US) launched a new clinical trial for a promising Alzheimer's treatment that utilizes a novel mechanism of action. This initiative is crucial as it reflects the company's dedication to exploring innovative therapeutic avenues, which may enhance its competitive edge in a market that is increasingly leaning towards personalized medicine. The trial's outcomes could significantly impact the treatment landscape, potentially establishing Eli Lilly as a leader in neurodegenerative therapies.
In August Biogen (US) expanded its partnership with a technology firm to integrate AI-driven analytics into its drug development processes. This strategic action is indicative of the growing trend towards digital transformation within the industry. By harnessing AI, Biogen aims to streamline its R&D efforts, reduce time-to-market for new therapies, and ultimately improve patient outcomes. This move not only enhances operational efficiency but also positions Biogen favorably against competitors who may lag in technological adoption.
As of November the competitive landscape is increasingly defined by trends such as digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and enhancing market presence. Looking ahead, it is likely that competitive differentiation will evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies approach market entry and product development, emphasizing the importance of agility and responsiveness in a rapidly changing environment.

## Recent News & Developments

In recent developments within the US Neurodegenerative Disease Market, a notable focus has been on Vertex Pharmaceuticals and Acadia Pharmaceuticals, which are advancing their pipelines for treatments related to various neurodegenerative conditions. In October 2023, AbbVie announced positive results from a phase 3 study for its Alzheimer’s drug, indicating progress in addressing cognitive decline. Furthermore, Biogen and Eli Lilly are engaged in collaborative Research and Development efforts aimed at innovative therapies for Alzheimer’s and related disorders, showcasing the trend of strategic partnerships in the industry.

Recent acquisitions include Amgen's strategic purchase of a biotech firm in August 2023, aiming to enhance its capabilities in neurodegenerative disease therapies. Acorda Therapeutics continues to experience growth attributed to its market strategies and product offerings, reflecting a broader trend of increasing market valuation across the sector, which is projected to expand significantly in the coming years. The ongoing investments and mergers signal a robust activity in tackling neurodegenerative diseases, with significant implications for patients and healthcare providers in the US. Major market players such as Roche and Novartis maintain competitive momentum through innovative clinical trials and product launches.

## Report Scope

| MARKET SIZE 2024 | 14.5(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 15.67(USD Billion) |
| MARKET SIZE 2035 | 34.0(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.05% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Biogen (US), Eli Lilly (US), Roche (CH), Novartis (CH), AstraZeneca (GB), Merck & Co. (US), Amgen (US), Sanofi (FR), AbbVie (US) |
| Segments Covered | Disease Type, Diagnosis Method, Treatment Type, Route of Administration |
| Key Market Opportunities | Advancements in personalized medicine and digital health technologies enhance treatment options in the neurodegenerative disease market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the neurodegenerative disease market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US neurodegenerative disease market?**
A: The market valuation was $14.5 Billion in 2024.

**Q: What is the projected market size for the US neurodegenerative disease market by 2035?**
A: The market is projected to reach $34.0 Billion by 2035.

**Q: What is the expected CAGR for the US neurodegenerative disease market during the forecast period 2025 - 2035?**
A: The expected CAGR is 8.05% during the forecast period.

**Q: Which companies are the key players in the US neurodegenerative disease market?**
A: Key players include Biogen, Eli Lilly, Roche, Novartis, AstraZeneca, Merck & Co., Amgen, Sanofi, and AbbVie.

**Q: What are the market segments based on disease type in the US neurodegenerative disease market?**
A: Segments include Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Huntington's Disease.

**Q: What was the market size for Alzheimer's Disease in 2024?**
A: The market size for Alzheimer's Disease was $5.0 Billion in 2024.

**Q: What is the projected market size for Parkinson's Disease by 2035?**
A: The projected market size for Parkinson's Disease is $7.0 Billion by 2035.

**Q: What are the primary treatment types in the US neurodegenerative disease market?**
A: Primary treatment types include Medication, Therapy, Rehabilitation, and Surgical Interventions.

**Q: What was the market size for rehabilitation in the US neurodegenerative disease market in 2024?**
A: The market size for Rehabilitation was $2.0 Billion in 2024.

**Q: What is the projected market size for injectable treatments by 2035?**
A: The projected market size for injectable treatments is $9.0 Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-neurodegenerative-disease-market-52780*